In this presentation I provided an update on the work of the SAFER Programme on screening for atrial fibrillation. The SAFER Programme is an ongoing body of research led by the University of Cambridge, investigating whether screening for atrial fibrillation is effective and cost effective in reducing stroke and other key outcomes compared to current practice. In this talk, I firstly consider the key questions which the research is addressing, and what is known about them so far. Secondly, I present our work on optimising the screening approach to reduce costs whilst maintaining its effectiveness. Thirdly, I provide some insights into what screening might look like in the future.
The following resources accompany this talk:
None of this would have been possible without: